Clatworthy, A.E., Pierson, E., Hung, D.T., Targeting virulence: A new paradigm for antimicrobial therapy (2007) Nat Chem Biol, 3, pp. 541-548; Liu, Y.C., Li, Y.S., Lyu, S.Y., Hsu, L.J., Chen, Y.H., Huang, Y.T., Chan, H.C., Li, T.L., Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds (2011) Nat Chem Biol, 7, pp. 304-309; Kristiansson, E., Fick, J., Janzon, A., Grabic, R., Rutgersson, C., Weijdegard, B., Soderstrom, H., Larsson, D.G., Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements (2011) PLoS ONE, 6, p. e17038; (2013), 2013. , www.cdc.gov/drugresistance/threat-report-2013/, CDCAntibiotic resistance threats in the United States; Hogberg, L.D., Heddini, A., Cars, O., The global need for effective antibiotics: Challenges and recent advantages (2010) Trends Pharmacol Sci, 31, pp. 509-515; (2014), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm, FDAFDA news release: FDA approves dalvance to treat skin infections; Corey, G.R., Kabler, H., Mehra, P., Gupta, S., Overcash, J.S., Porwal, A., Giordano, P., O'Riordan, W., Single-dose oritavancin in the treatment of acute bacterial skin infections (2014) N Engl J Med, 370, pp. 2180-2190. , SOLO I Investigators; Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Bartlet, J., Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America (2009) Clin Infect Dis, 48, pp. 1-12; Higgins, P.G., Dammhayn, C., Hackel, M., Seifert, H., Global spread of carbapenem-resistant Acinetobacter baumannii (2010) J Antimicrob Chemother, 65, pp. 233-238; Van Duin, D., Kaye, K.S., Neuner, E.A., Bonomo, R.A., Carbapenem-resistant enterobacteriaceae: A review of treatment and outcomes (2013) Diagn Microbiol Infect Dis, 75, pp. 115-120; Spellberg, B., Blaser, M., Guidos, R.J., Boucher, H.W., Bradley, J.S., Eisenstein, B.I., Gerding, D., Gilbert, D.N., Combating antimicrobial resistance: Policy recommendations to save lives (2011) Clin Infect Dis, 52, pp. S397-S428; Shlaes, D.M., New β-lactam-β-lactamase inhibitor combinations in clinical development (2013) Ann NY Acad Sci, 1277, pp. 105-114; Abuzaid, A., Hamouda, A., Amyes, S.G., Klebsiella pneumoniae susceptibility to biocides and its association with cepA, qacΔE and qacE efflux pump genes and antibiotic resistance (2012) J Hosp Infect, 81, pp. 87-91; Urakawa, H., Yamada, K., Komagoe, K., Ando, S., Oku, H., Katsu, T., Matsuo, I., Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides (2010) Bioorg Med Chem Lett, 20, pp. 1771-1775; Bush, K., Improving known classes of antibiotics: An optimistic approach for the future (2012) Curr Opin Pharmacol, 12, pp. 527-534; Pucci, M.J., Bush, K., Investigational antimicrobial agents of 2013 (2013) Clin Microbiol Rev, 26, pp. 792-821; Palzkill, T., Metallo-β-lactamase structure and function (2013) Ann N y Acad Sci, 1277, pp. 91-104; Bush, K., Jacoby, G.A., Medeiros, A.A., A functional classification scheme for β-lactamases and its correlation with molecular structure (1995) Antimicrob Agents Chemother, 39, pp. 1211-1233; Stachyra, T., Pechereau, M.C., Bruneau, J.M., Claudon, M., Frere, J.M., Miossec, C., Coleman, K., Black, M.T., Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor (2010) Antimicrob Agents Chemother, 54, pp. 5132-5138; Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Kern, G., Walkup, G.K., Fisher, S.L., Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor (2012) Proc Natl Acad Sci USA, 109, pp. 11663-11668; Levasseur, P., Girard, A.M., Claudon, M., Goossens, H., Black, M.T., Coleman, K., Miossec, C., In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates (2012) Antimicrob Agents Chemother, 56, pp. 1606-1608; Flamm, R.K., Farrell, D.J., Sader, H.S., Jones, R.N., Ceftazidime/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012) (2014) J Antimicrob Chemother, 69, pp. 1589-1598; Blizzard, T.A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., Imbriglio, J., Al, E., Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin® (2014) Bioorg Med Chem Lett, 24, pp. 780-785; Hecker, S.J., Reddy, K.R., Totrov, M., Hirst, G.C., Lomovskaya, O., Griffith, D.C., King, P., Dudley, M.N., (2012) Discovery of RPX7009, A Broad-spectrum Beta-lactamase Inhibitor with Utility Versus Class A Serine Carbapenemases, , http://www.icaac.org/, Abstr 52nd Intersci Conf Antimicrob Agents Chemother; Winkler, M.L., Rodkey, E.A., Taracila, M.A., Drawz, S.M., Bethel, C.R., Papp-Wallace, K.M., Smith, K.M., Bonomo, R.A., Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase (2013) J Med Chem, 56, pp. 1084-1097; Mondon, M., Hur, S., Vadlamani, G., Rodrigues, P., Tsybina, P., Oliver, A., Mark, B.L., Blériot, Y., Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to β-lactams (2013) Chem Commun (Camb), 49, pp. 10983-10985; Rodkey, E.A., Winkler, M.L., Bethel, C.R., Pagadala, S.R., Buynak, J.D., Bonomo, R.A., Van Den Akker, F., Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition (2014) PLoS ONE, 9, p. e85892; Gan, M., Liu, Y., Bai, Y., Guan, Y., Li, L., Gao, R., He, W., Xiao, C., Polyketides with New Delhi metallo-β-lactamase 1 inhibitory activity from Penicillium sp (2013) J Nat Prod, 76, pp. 1535-1540; Yamada, K., Yanagihara, K., Kaku, N., Harada, Y., Migiyama, Y., Nagaoka, K., Morinaga, Y., Kohno, S., In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa (2013) Int J Antimicrob Agents, 42, pp. 238-243; Higgins, P.G., Stefanik, D., Page, M.G., Hackel, M., Seifert, H., In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non- susceptible Acinetobacter baumannii (2012) J Antimicrob Chemother, 67, pp. 1167-1169; Bush, K., Macielag, M.J., New β-lactam antibiotics and β-lactamase inhibitors (2010) Expert Opin Ther Pat, 20, pp. 1277-1293; Tilvawala, R., Pratt, R.F., Kinetics of action of a two-stage pro-inhibitor of serine β-lactamases (2013) Biochemistry, 52, pp. 7060-7070; King, A.M., Reid-Yu, S.A., Wang, W., King, D.T., De Pascale, G., Strynadka, N.C., Walsh, T.R., Wright, G.D., Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance (2014) Nature, 510, pp. 503-506; Zhang, J.I., Chen, Y.P., Miller, K.P., Ganewatta, M.S., Bam, M., Yan, Y., Nagarkatti, M., Tang, C., Antimicrobial metallopolymers and their bioconjugates with conventional antibiotics against multidrug-resistant bacteria (2014) J Am Chem Soc, 136, pp. 4873-4876; Yuan, J., Chow, D.C., Huang, W., Palzkill, T., Identification of a β-lactamase inhibitory protein variant that is a potent inhibitor of Staphylococcus PC1 β-lactamase (2011) J Mol Biol, 406, pp. 730-744; Chen, X., Li, L., Chen, S., Xu, Y., Xia, Q., Guo, Y., Liu, X., Shui, W., Identification of inhibitors of the antibiotic-resistance target New Delhi metallo-β-lactamase 1 by both nanoelectrospray ionization mass spectrometry and ultrafiltration liquid chromatography/mass spectrometry approaches (2013) Anal Chem, 85, pp. 7957-7965; Sohier, J.S., Laurent, C., Chevigné, A., Pardon, E., Srinivasan, V., Wernery, U., Lassaux, P., Galleni, M., Allosteric inhibition of VIM metallo-β-lactamases by a camelid nanobody (2013) Biochem J, 450, pp. 477-486; Ripoll, A., Galán, J.C., Rodríguez, C., Tormo, N., Gimeno, C., Baquero, F., Martínez-Martínez, L., Cantõn, R., Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: A multicenter external proficiency study using a well-defined collection of Escherichia coli strains (2014) J Clin Microbiol, 52, pp. 122-129. , SEIMC Quality Control Study Group; Biot, F.V., Valade, E., Garnotel, E., Chevalier, J., Villard, C., Thibault, F.M., Vidal, D.R., Pagès, J.M., Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: Proteomic and mechanistic evidence (2011) PLoS ONE, 6, p. e16892; Biot, F.V., Lopez, M.M., Poyot, T., Neulat-Ripoll, F., Lignon, S., Caclard, A., Thibault, F.M., Valade, E., Interplay between three RND efflux pumps in doxycycline-selected strains of Burkholderia thailandensis (2013) PLoS ONE, 8, p. e84068; Lamers, R.P., Cavallari, J.F., Burrows, L.L., The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria (2013) PLoS ONE, 8, p. e60666; Kumar, A., Schweizer, H.P., Bacterial resistance to antibiotics: Active efflux and reduced uptake (2005) Adv Drug Deliv Rev, 57, pp. 1486-1513; Ince, D., Zhang, X., Silver, L.C., Hooper, D.C., Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone (2002) Antimicrob Agents Chemother, 46, pp. 3370-3380; Strahilevitz, J., Truong-Bolduc, Q.C., Hooper, D.C., DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: Quinolone resistance beyond modification of type II topoisomerases (2005) Antimicrob Agents Chemother, 49, pp. 5051-5057; Da Silva, P.E.A., Von Groll, A., Martin, A., Palomino, J.C., Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis (2011) FEMS Immunol Med Microbiol, 63, p. 1e9; Roy, S.K., Kumari, N., Gupta, S., Pahwa, S., Nandanwar, H., Jachak, S.M., 7-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc 155 (2013) Eur J Med Chem, 66, pp. 499-507; Paulasova, P., Pellestor, F., The peptide nucleic acids (PNAs): A new generation of probes for genetic and cytogenetic analyses (2004) Ann Genet, 47, pp. 349-358; Jeon, B., Zhang, Q., Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the Cme- ABC multidrug efflux transporter (2009) J Antimicrob Chemother, 63, pp. 946-948; Mu, Y., Shen, Z., Jeon, B., Dai, L., Zhang, Q., Synergistic effects of anti-CmeA and anti-CmeB peptide nucleic acids on sensitizing Campylobacter jejuni to antibiotics (2013) Antimicrob Agents Chemother, 57, pp. 4575-4577; Oh, E., Zhang, Q., Jeon, B., Target optimization for peptide nucleic acid (PNA)-mediated antisense inhibition of the CmeABC multidrug efflux pump in Campylobacter jejuni (2014) J Antimicrob Chemother, 69, pp. 375-380; Noumedem, J.A., Mihasan, M., Kuiate, J.R., Stefan, M., Cojocaru, D., Dzoyem, J.P., Kuete, V., In vitro antibacterial and antibiotic-potentiation activities of four edible plants against multidrug-resistant gram-negative species (2013) BMC Complement Altern Med, 13, p. 190; Lacmata, S.T., Kuete, V., Dzoyem, J.P., Tankeo, S.B., Teke, G.N., Kuiate, J.R., Pages, J.M., Antibacterial activities of selected Cameroonian plants and their synergistic effects with antibiotics against bacteria expressing MDR phenotypes (2012) Evid Based Complement Alternat Med, 2012, p. 623723; Hancock, R.E.W., The Pseudomonas aeruginosa outer membrane permeability barrier and how to overcome it (1985) Antibiot Chemother, 36, pp. 95-102; Hancock, R.E.W., Peptide antibiotics (1997) Lancet, 349, pp. 418-422; Hancock, R.E.W., Wong, P.G.W., Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane (1984) Antimicrob Agents Chemother, 26, pp. 48-52; Scott, M.G., Yan, H., Hancock, R.E.W., Biological properties of structurally related α-helical cationic antimicrobial peptides (1999) Infect Immun, 67, pp. 2005-2009; Savage, P.B., Multidrug-resistant bacteria: Overcoming antibiotic permeability barriers of gram-negative bacteria (2001) Ann Med, 33, pp. 167-171; Schmidt, E.J., Boswell, J.S., Walsh, J.P., Schellenberg, M.M., Winter, T.W., Li, C., Allman, G.W., Savage, P.B., Activities of cholic acid-derived antimicrobial agents against multidrug-resistant bacteria (2001) J Antimicrob Chemother, 47, pp. 671-674; Vaara, M., Agents that increase the permeability of the outer membrane (1991) Microbiol Rev, 56, pp. 395-411; Briers, Y., Walmagh, M., Lavigne, R., Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa (2011) J Appl Microbiol, 110, pp. 778-785; Ando, M., Kamei, R., Komagoe, K., Inoue, T., Yamada, K., Katsu, T., In situ potentiometric method to evaluate bacterial outer membrane-permeabilizing ability of drugs: Example using antiprotozoal diamidines (2012) J Microbiol Methods, 91, pp. 497-500; Kwon, D.H., Lu, C.D., Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa (2006) Antimicrob Agents Chemother, 50, pp. 1623-1627; Guha, A., Choudhury, A., Unni, B.G., Roy, M.K., Effect of outer-membrane permeabilizers on the activity of antibiotics and plant extracts against Pseudomonas aeruginosa (2002) Folia Microbiol (Praha), 47, pp. 379-384; Chatterjee, S., Bijsmans, I.T., Van Mil, S.W., Augustijns, P., Annaert, P., Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: Role of glycine conjugates (2014) Toxicol in Vitro, 28, pp. 218-230; De La Fuente-Núñez, C., Reffuveille, F., Haney, E.F., Strauss, S.K., Hancock, R.E.W., Broad-spectrum anti-biofilm peptide that targets a cellular stress response (2014) PLoS Pathog, 10, p. e1004152; Reffuveille, F., De La Fuente-Núñez, C., Mansour, S., Hancock, R.E.W., A broad-spectrum anti-biofilm peptide enhances action against bacterial biofilms (2014) Antimicrob Agents Chemother, 58, pp. 5363-5371; Overhage, J., Campisano, A., Bains, M., Torfs, E.C.W., Rehm, B.H.A., Hancock, R.E.W., Human host defense peptide LL-37 prevents bacterial biofilm formation (2008) Infect Immun, 76, pp. 4176-4182; De La Fuente-Núñez, C., Korolik, V., Bains, M., Nguyen, U., Breidenstein, E.B.M., Horsman, S., Lewenza, S., Hancock, R.E.W., Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide (2012) Antimicrob Agents Chemother, 56, pp. 2696-2704; De La Fuente-Núñez, C., Reffuveille, F., Fernández, L., Hancock, R.E.W., Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies (2013) Curr Opinion Microbiol, 16, pp. 580-589; Ho Sui, S.J., Fedynak, A., Hsiao, W.W., Langille, M.G., Brinkman, F.S., The association of virulence factors with genomic islands (2009) PLoS ONE, 4, p. e8094; Rasko, D.A., Sperandio, V., Anti-virulence strategies to combat bacteria-mediated disease (2010) Nat Rev Drug Discov, 9, pp. 117-128; Fernebro, J., Fighting bacterial infections - Future treatment options (2011) Drug Resist Update, 14, pp. 125-139; Antunes, L.C., Ferreira, R.B., Buckner, M.M., Finlay, B.B., Quorum sensing in bacterial virulence (2010) Microbiology, 156, pp. 2271-2282; Gilbert, K.B., Kim, T.H., Gupta, R., Greenberg, E.P., Schuster, M., Global position analysis of the Pseudomonas aeruginosa quorum-sensing transcription factor LasR (2009) Mol Microbiol, 73, pp. 1072-1085; Schuster, M., Lostroh, C.P., Ogi, T., Greenberg, E.P., Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: A transcriptome analysis (2003) J Bacteriol, 185, pp. 2066-2079; Deziel, E., Gopalan, S., Tampakaki, A.P., Lepine, F., Padfield, K.E., Saucier, M., Xiao, G., Rahme, L.G., The contribution of MvfR to Pseudomonas aeruginosa pathogenesis and quorum sensing circuitry regulation: Multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-homoserine lactones (2005) Mol Microbiol, 55, pp. 998-1014; De Kievit, T.R., Iglewski, B.H., Bacterial quorum sensing in pathogenic relationships (2000) Infect Immun, 68, pp. 4839-4849; Lequette, Y., Lee, J.H., Ledgham, F., Lazdunski, A., Greenberg, E.P., A distinct QscR regulon in the Pseudomonas aeruginosa quorum-sensing circuit (2006) J Bacteriol, 188, pp. 3365-3370; Latifi, A., Foglino, M., Tanaka, K., Williams, P., Lazdunski, A., A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS (1996) Mol Microbiol, 21, pp. 1137-1146; Diggle, S.P., Cornelis, P., Williams, P., Camara, M., 4-quinolone signalling in Pseudomonas aeruginosa: Old molecules, new perspectives (2006) Int J Med Microbiol, 296, pp. 83-91; Jimenez, P.N., Koch, G., Thompson, J.A., Xavier, K.B., Cool, R.H., Quax, W.J., The multiple signaling systems regulating virulence in Pseudomonas aeruginosa (2012) Microbiol Mol Biol Rev, 76, pp. 46-65; Davies, D.G., Parsek, M.R., Pearson, J.P., Iglewski, B.H., Costerton, J.W., Greenberg, E.P., The involvement of cell-to-cell signals in the development of a bacterial biofilm (1998) Science, 280, pp. 295-298; Rumbaugh, K.P., Griswold, J.A., Iglewski, B.H., Hamood, A.N., Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections (1999) Infect Immun, 67, pp. 5854-5862; O'Loughlin, C.T., Miller, L.C., Siryaporn, A., Drescher, K., Semmelhack, M.F., Bassler, B.L., A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation (2013) Proc Natl Acad Sci USA, 110, pp. 17981-17986; Tan, S.Y., Chua, S.L., Chen, Y., Rice, S.A., Kjelleberg, S., Nielsen, T.E., Yang, L., Givskov, M., Identification of five structurally unrelated quorum-sensing inhibitors of Pseudomonas aeruginosa from a natural-derivative database (2013) Antimicrob Agents Chemother, 11, pp. 5629-5641; Sully, E.K., Malachowa, N., Elmore, B.O., Alexander, S.M., Femling, J.K., Gray, B.M., Deleo, F.R., Gresham, H.D., Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance (2014) PLoS Pathog, 10, p. e1004174; Hentzer, M., Riedel, K., Rasmussen, T.B., Heydorn, A., Andersen, J.B., Parsek, M.R., Rice, S.A., Givskov, M., Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound (2002) Microbiology, 148, pp. 87-102; Hentzer, M., Wu, H., Andersen, J.B., Riedel, K., Rasmussen, T.B., Bagge, N., Kumar, N., Al, E., Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors (2003) EMBO J, 22, pp. 3803-3815; Pustenly, C., Albers, A., Buldt-Karentzopoulos, K., Parschat, K., Chhabra, S.R., Camara, M., Williams, P., Fetzner, S., Dioxygenase-mediated quenching of quinolone-dependent quorum sensing in Pseudomonas aeruginosa (2009) Chem Biol, 12, pp. 1259-1267; Uroz, S., Chhabra, S.R., Camara, M., Williams, P., Oger, P., Dessaux, Y., N-Acylhomoserine lactone quorum-sensing molecules are modified and degraded by Rhodococcus erythropolis W2 by both amidolytic and novel oxidoreductase activities (2005) Microbiol, 151, pp. 3313-3322; Chow, J.Y., Yang, Y., Tay, S.B., Chua, K.L., Yew, W.S., Disruption of biofilm formation by the human pathogen Acinetobacter baumannii using engineered quorum-quenching lactonases (2014) Antimicrob Agents Chemother, 58, pp. 1802-1805; Christensen, Q.H., Grove, T.L., Booker, S.J., Greenberg, E.P., A high-throughput screen for quorum-sensing inhibitors that target acyl-homoserine lactone synthases (2013) Proc Natl Acad Sci USA, 110, pp. 13815-13820; Schiavo, G., Van Der Goot, G.F., The bacterial toxin toolkit (2001) Nat Rev Mol Cell Biol, 2, pp. 530-537; Endo, Y., Tsurugi, K., Yutsudo, T., Takeda, Y., Ogasawara, T., Igarashi, K., Site of action of a vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins (1988) Eur J Biochem, 171, pp. 45-50; Orth, P., Xiao, L., Hernandez, L.D., Reichert, P., Sheth, P.R., Beaumont, M., Yang, X., Al, E., Mechanism of action and epitopes of Clostridium difficile toxin B neutralizing antibody bezotoxumab revealed by x-ray crystallography (2014) J Biol Chem, 289, pp. 18008-18021; Berube, B.J., Wardenburg, J.B., Staphylococcus aureus alpha-toxin: Nearly a century of intrigue (2013) Toxins, 5, pp. 1140-1166; Lopez, E.L., Contrini, M.M., Glatstein, E., Gonzalez Ayala, S., Sontoro, R., Allende, D., Ezcurra, G., Al, E., Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with shiga-like toxin producing Escherichia coli (2010) Antimicrob Agents Chemother, 54, pp. 239-243; Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Berding, D.N., Nichol, G., Ambrosino, D.M., Treatment with monoclonal antibodies against Clostridium difficile toxins (2010) N Engl J Med, 362, pp. 197-205; Nivaskumar, M., Francetic, O., Type II secretion system: A magic beanstalk or a protein escalator (2014) Biochim Biophys Acta, 1843, pp. 1568-1577; Korotkov, K.V., Sandkvist, M., Hol, W.G., The type II secretion system: Biogenesis, molecular architecture and mechanism (2012) Nat Rev Microbiol, 10, pp. 336-351; Braun, P., De Groot, A., Bitter, W., Tommassen, J., Secretion of elastinolytic enzymes and their propeptides by Pseudomonas aeruginosa (1998) J Bacteriol, 180, pp. 3467-3469; Voulhoux, R., Ball, G., Ize, B., Vasil, M.L., Lazdunski, A., Wu, L.F., Filloux, A., Involvement of the twin-arginine translocation system in protein secretion via the type II pathway (2001) EMBO J, 20, pp. 6735-6741; Baldi, D.L., Higginson, E.E., Hocking, D.M., Praszkier, J., Cavaliere, R., James, C.E., Bennett-Wood, V., Tauschek, M., The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli (2012) Infect Immun, 80, pp. 2042-2052; Moir, D.T., Di, M., Wong, E., Moore, R.A., Schweizer, H.P., Woods, D.E., Bowlin, T.L., Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei (2011) J Biomol Screen, 16, pp. 694-705; Segers, K., Anne, J., Traffic jam at the bacterial sec translocase: Targeting the SecA nanomotor by small-molecule inhibitors (2011) Chem Biol, 18, pp. 685-698; Chatterjee, S., Chaudhury, S., McShan, A.C., Kaur, K., De Guzman, R.N., Structure and biophysics of type III secretion in bacteria (2013) Biochemistry, 52, pp. 2508-2517; Engel, J., Balachandran, P., Role of Pseudomonas aeruginosa type III effectors in disease (2009) Curr Opin Microbiol, 12, pp. 61-66; Dean, P., Functional domains and motifs of bacterial type III effector proteins and their roles in infection (2011) FEMS Microbiol Rev, 35, pp. 1100-1125; Yamazaki, A., Li, J., Zeng, Q., Khokhani, D., Hutchins, W.C., Yost, A.C., Biddle, E., Yang, C.H., Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system (2012) Antimicrob Agents Chemother, 56, pp. 36-43; Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H., Elofsson, M., Targeting bacterial virulence: Inhibitors of type III secretion in Yersinia (2003) Chem Biol, 10, pp. 241-249; Tree, J.J., Wang, D., McInally, C., Mahajan, A., Layton, A., Houghton, I., Elofsson, M., Roe, A.J., Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7 (2009) Infect Immun, 77, pp. 4209-4220; Wang, D., Zetterstrom, C.E., Gabrielsen, M., Beckham, K.S., Tree, J.J., Macdonald, S.E., Byron, O., Al, E., Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds (2011) J Biol Chem, 286, pp. 29922-29931; Larzabal, M., Zotta, E., Ibarra, C., Rabinovitz, B.C., Vilte, D.A., Mercado, E.C., Cataldi, A., Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorragic Escherichia coli O157:H7 and Citrobacter rodentium (2013) Int J Med Microbiol, 303, pp. 9-15; Larzabal, M., Mercado, E.C., Vilte, D.A., Salazar-Gonzalez, H., Cataldi, A., Navarro-Garcia, F., Designed coiled-coil peptides inhibit the type three secretion system of enteropathogenic Escherichia coli (2010) PLoS ONE, 5, p. e9046; Kimura, K., Iwatsuki, M., Nagai, T., Matsumoto, A., Takahashi, Y., Shiomi, K., Omura, S., Abe, A., A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium (2011) J Antibiot, 64, pp. 197-203; Hogg, T., Mesters, J.R., Hilgenfeld, R., Inhibitory mechanisms of antibiotics targeting elongation factor Tu (2002) Curr Protein Pept Sci, 3, pp. 121-131; Kohler, T., Perron, G.G., Buckling, A., Van Delden, C., Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa (2010) PLoS Pathog, 6, p. e1000883; Maeda, T., Garcia-Contreras, R., Pu, M., Sheng, L., Garcia, L.R., Tomas, M., Wood, T.K., Quorum quenching quandary: Resistance to anti-virulence compounds (2012) ISME J, 6, pp. 493-501; Kumar, H., Kawai, T., Akira, S., Pathogen recognition by the innate immune system (2011) Int Rev Immunol, 30, pp. 16-34; Regan, T., Nally, K., Carmody, R., Houston, A., Shanahan, F., Macsharry, J., Brint, E., Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages (2013) J Immunol, 191, pp. 6084-6092; Schreibelt, G., Tel, J., Sliepen, K.H., Benitez-Ribas, D., Figdor, C.G., Adema, G.J., De Vries, I.J., Toll-like receptor expression and function in human dendritic cell subsets: Implications for dendritic cell-based anti-cancer immunotherapy (2010) Cancer Immunol Immunother, 59, pp. 1573-1582; Orr, M.T., Beebe, E.A., Hudson, T.E., Moon, J.J., Fox, C.B., Reed, S.G., Coler, R.N., A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93 (2014) PLoS ONE, 9, p. e83884; Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Pulendran, B., Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity (2006) J Exp Med, 203, pp. 413-424; Schreibelt, G., Benitez-Ribas, D., Schuurhuis, D., Lambeck, A.J., Van Hout-Kuijer, M., Schaft, N., Punt, C.J., De Vries, I.J., Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells (2010) Blood, 116, pp. 564-574; De, Y., Chen, Q., Schmidt, A.P., Anderson, G.M., Wang, J.M., Wooters, J., Oppenheim, J.J., Chertov, O., LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells (2000) J Exp Med, 192, pp. 1069-1074; Zheng, Y., Niyonsaba, F., Ushio, H., Nagaoka, I., Ikeda, S., Okumura, K., Ogawa, H., Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils (2007) Br J Dermatol, 157, pp. 1124-1131; Mookherjee, N., Brown, K.L., Bowdish, D.M., Doria, S., Falsafi, R., Hokamp, K., Roche, F.M., Hancock, R.E.W., Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37 (2006) J Immunol, 176, pp. 2455-2464; Nijnik, A., Pistolic, J., Wyatt, A., Tam, S., Hancock, R.E.W., Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs (2009) J Immunol, 183, pp. 5788-5798; Koczulla, R., Von Degenfeld, G., Kupatt, C., Krotz, F., Zahler, S., Gloe, T., Issbrucker, K., Al, E., An angiogenic role for the human peptide antibiotic LL-37/hCAP-18 (2003) J Clin Invest, 111, pp. 1665-1672; Shaykhiev, R., Beisswenger, C., Kandler, K., Senske, J., Puchner, A., Damm, T., Behr, J., Bals, R., Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure (2005) Am J Physiol Lung Cell Mol Physiol, 289, pp. L842-L848; Steinstraesser, L., Hirsch, T., Schulte, M., Kueckelhaus, M., Jacobsen, F., Mersch, E.A., Stricker, I., Kindrachuk, J., Innate defense regulator peptide 1018 in wound healing and wound infection (2012) PLoS ONE, 7, p. e39373; Cirioni, O., Giacometti, A., Ghiselli, R., Bergnach, C., Orlando, F., Silvestri, C., Mocchegiani, F., Scalise, G., LL-37 protects rats against lethal sepsis caused by gram-negative bacteria (2006) Antimicrob Agents Chemother, 50, pp. 1672-1679; Rivas-Santiago, B., Castaneda-Delgado, J.E., Rivas Santiago, C.E., Waldbrook, M., Gonzalez-Curiel, I., Leon-Contreras, J.C., Enciso-Moreno, J.A., Hernandez-Pando, R., Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models (2013) PLoS ONE, 8, p. e59119; Achtman, A.H., Pilat, S., Law, C.W., Lynn, D.J., Janot, L., Mayer, M.L., Ma, S., Schofield, L., Effective adjunctive therapy by an innate defense regulatory peptide in a pre-clinical model of severe malaria (2012) Sci Trasl Med, 4, p. 135ra64; Faber, C., Stallmann, H.P., Lyaruu, D.M., Joosten, U., Von Eiff, C., Van Nieuw Amerongen, A., Wuisman, P.I., Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model (2005) Antimicrob Agents Chemother, 49, pp. 2438-2444; Velden, W.J., Van Iersel, T.M., Blijlevens, N.M., Donnelly, J.P., Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) (2009) BMC Med, 7, p. 44; Papareddy, P., Kalle, M., Sorensen, O.E., Malmsten, M., Morgelin, M., Schmidtchen, A., The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis (2013) PLoS Pathog, 9, p. e1003803; Easton, D.M., Nijnik, A., Mayer, M.L., Hancock, R.E.W., Potential of immunomodulatory host defense peptides as novel anti-infectives (2009) Trends Biotechnol, 27, pp. 582-590; (2013) World Health OrganizationDiarrhoeal Disease, , http://www.who.int/mediacentre/factsheets/fs330/en/, Fact sheet No. 330; Mandal, S.M., Dey, S., Mandal, M., Sarkar, S., Maria-Neto, S., Franco, O.L., Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water (2009) Peptides, 30, pp. 633-637; Ciglenecki, I., Bichet, M., Tena, J., Mondesir, E., Bastard, M., Tran, N.T., Antierens, A., Staderini, N., Cholera in pregnancy: Outcomes from a specialized cholera treatment unit for pregnant women in Léogâne, Haiti (2013) PLoS Negl Trop Dis, 7, p. e2368; Sulakvelidze, A., Alavidze, Z., Morris, J.G., Jr., Bacteriophage therapy (2001) Antimicrob Agents Chemother, 45, pp. 649-659; D'Herelle, F., Surun microbe invisible antagoniste des bacteries dysenteriques (1917) C R Acad Sci, 165, pp. 373-375; Hausler, T., (2006) Viruses Versus Superbugs. A Solution to the Antibiotic Crisis?, , New York: Palgrave Macmillan; Skurnika, M., Strauch, E., Phage therapy: Facts and fiction (2006) Intern J Med Microbiol, 296, pp. 5-14; Inal, J.M., Phage therapy: A reappraisal of bacteriophages as antibiotics (2003) Arch Immunol Ther Exp (Warsz), 51, pp. 237-244; Brüssow, H., Canchaya, C., Hardt, W.D., Phages and the evolution of bacterial pathogens: From genomic rearrangements to lysogenic conversion (2004) Microbiol Mol Biol Rev, 68, pp. 560-602; Mandal, S.M., Roy, A., Ghosh, A.K., Hazra, T.K., Basak, A., Franco, O.L., Challenges and future prospects of antibiotic therapy: From peptides to phages utilization (2014) Front Pharmac, 5, p. 105; Khairnar, K., Raut, M.P., Chandekar, R.H., Sanmukh, S.G., Paunikar, W.N., Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in catfish (2013) BMC Vet Res, 26, p. 264; Drilling, A., Morales, S., Boase, S., Jervis-Bardy, J., James, C., Jardeleza, C., Tan, N.C., Wormald, P.J., Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis (2014) Int Forum Allergy Rhinol, 4, pp. 176-186; Lungren, M.P., Christensen, D., Kankotia, R., Falk, I., Paxton, B.E., Kim, C.Y., Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material (2013) Bacteriophage, 3, p. e26825; Parfitt, T., Georgia: An unlikely stronghold for bacteriophage therapy (2005) Lancet, 365, pp. 2166-2167; Thiel, K., Old dogma, new tricks - 21st Century phage therapy (2004) Nat Biotechn, 22, pp. 31-36; Lu, T.K., Collins, J.J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy (2009) Proc Natl Acad Sci USA, 106, pp. 4629-4634; Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., Schmidt, M.G., Norris, J.S., Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections (2003) Antimicrob Agents Chemother, 47, pp. 1301-1307; Walsh, C.J., Guinane, C.M., O'Toole, P.W., Cotter, P.D., Beneficial modulation of the gut microbiota (2014) FEBS Lett, 588, pp. 4120-4130; Lilly, D.M., Stillwell, R.H., Probiotics: Growth-promoting factors produced by microorganisms (1965) Science, 147, pp. 747-748; Volzing, K., Borrero, J., Sadowsky, M.J., Kaznessis, Y.N., Antimicrobial peptides targeting gram-negative pathogens, produced and delivered by lactic acid bacteria (2013) ACS Synth Biol, 2, pp. 643-650; Lu, L., Walker, W.A., Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium (2001) Am J Clin Nutr, 73, pp. 1124-1130; Carr, F.J., Chill, D., Maida, N., The lactic acid bacteria: A literature survey (2002) Crit Rev Microbiol, 28, pp. 281-370; Hassan, M., Kjos, M., Nes, I.F., Diep, D.B., Lotfipour, F., Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance (2012) J Appl Microbiol, 113, pp. 723-736; Mandal, S.M., Silva, O.N., Franco, O.L., Recombinant probiotics with antimicrobial peptides: A dual strategy to improve immune response in immunocompromised patients (2014) Drug Discov Today, 19, pp. 1045-1050; Petschow, B., Doré, J., Hibberd, P., Dinan, T., Reid, G., Blaser, M., Cani, P.D., Al, E., Probiotics, prebiotics, and the host microbiome: The science of translation (2013) Ann N y Acad Sci, 1306, pp. 1-17; Tahlan, K., Park, H.U., Wong, A., Beatty, P.H., Jensen, S.E., Two sets of paralogous genes encode the enzymes involved in the early stages of clavulanic acid and clavam metabolite biosynthesis in Streptomyces clavuligerus (2004) Antimicrob Agents Chemother, 48, pp. 930-939; Totir, M.A., Helfand, M.S., Carey, M.P., Sheri, A., Buynak, J.D., Bonomo, R.A., Cary, P.R., Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 β-lactamase (2007) Biochemistry, 46, pp. 8980-8987; Carlier, M., Carrette, S., Stove, V., Verstraete, A.G., De Waele, J.J., Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course (2014) Int J Antimicrob Agents, 14, pp. S0924-S8579; Coleman, K., Levasseur, P., Girard, A.M., Borgonovi, M., Miossec, C., Merdjan, H., Drusano, G., Nichols, W.W., The activity of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model (2014) Antimicrob Agents Chemother, 58, pp. 3366-3372; Castanheira, M., Williams, G., Jones, R.N., Sader, H.S., Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States (2014) Microb Drug Resist, 20, pp. 436-440; Livermore, D.M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., Woodford, N., Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing enterobacteriaceae (2011) Antimicrob Agents Chemother, 55, pp. 390-394; Hiraiwa, Y., Morinaka, A., Fukushima, T., Kudo, T., Metallo-β-lactamase inhibitory activity of 3-alkyloxy and 3-amino phthalic acid derivatives and their combination effect with carbapenem (2013) Bioorg Med Chem, 21, pp. 5841-5850; Toney, J.H., Hammond, G.G., Fitzgerald, P.M.D., Sharma, N., Balkovec, J.M., Rouen, G.P., Olson, S.H., Gao, Y.D., Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-β-lactamase (2001) J Biol Chem, 276, pp. 31913-31918; Goldstein, E.J., Citron, D.M., Tyrrell, K.L., Merriam, C.V., In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria (2013) Antimicrob Agents Chemother, 57, pp. 2620-2630; Fontaine, F., Hequet, A., Voisin-Chiret, A.S., Bouillon, A., Lesnard, A., Cresteil, T., Jolivalt, C., Rault, S., First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump (2014) J Med Chem, 57, pp. 2536-2548; Hequet, A., Burchak, O.N., Jeanty, M., Guinchard, X., Le Pihive, E., Maigre, L., Bouhours, P., Jolivalt, C., 1-(1H-Indol-3-yl)ethanamine derivatives as potent Staphylococcus aureus NorA efflux pump inhibitors (2014) Chem Med Chem, 9, pp. 1534-1545; Kalia, N.P., Mahajan, P., Mehra, R., Nargotra, A., Sharma, J.P., Koul, S., Khan, I.A., Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus (2012) J Antimicrob Chemother, 67, pp. 2401-2408; Sabatini, S., Gosetto, F., Serritella, S., Manfroni, G., Tabarrini, O., Iraci, N., Brincat, J.P., Cecchetti, V., Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: A promising new class of Staphylococcus aureus NorA efflux pump inhibitors (2012) J Med Chem, 55, pp. 3568-3572; Sabatini, S., Gosetto, F., Manfroni, G., Tabarrini, O., Kaatz, G.W., Patel, D., Cecchetti, V., Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S aureus NorA efflux pump (2011) J Med Chem, 54, pp. 5722-5736; Brincat, J.P., Carosati, E., Sabatini, S., Manfroni, G., Fravolini, A., Raygada, J.L., Patel, D., Cruciani, G., Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus (2011) J Med Chem, 54, pp. 354-365; Thota, N., Reddy, M.V., Kumar, A., Khan, I.A., Sangwan, P.L., Kalia, N.P., Koul, J.L., Koul, S., Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus (2010) Eur J Med Chem, 45, pp. 3607-3616